Compare ANNX & NX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | NX |
|---|---|---|
| Founded | 2011 | 1927 |
| Country | United States | United States |
| Employees | N/A | 7071 |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.5M | 915.5M |
| IPO Year | 2020 | 2008 |
| Metric | ANNX | NX |
|---|---|---|
| Price | $5.79 | $19.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $16.50 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 2.2M | 309.6K |
| Earning Date | 05-11-2026 | 06-04-2026 |
| Dividend Yield | N/A | ★ 1.64% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,837,641,000.00 |
| Revenue This Year | N/A | $4.26 |
| Revenue Next Year | $16,320.74 | $1.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.81 |
| 52 Week Low | $1.60 | $11.04 |
| 52 Week High | $7.18 | $22.90 |
| Indicator | ANNX | NX |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 53.67 |
| Support Level | $4.79 | $18.92 |
| Resistance Level | $6.56 | $20.08 |
| Average True Range (ATR) | 0.29 | 0.73 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 8.43 | 41.23 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.